Novo Nordisk has acquired Akero Therapeutics for an undisclosed amount. Akero Therapeutics is a clinical-stage company focused on developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, particularly metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently undergoing evaluation in a 96-week Phase 2b clinical trial, the SYMMETRY study, for patients with compensated cirrhosis due to MASH. Additionally, EFX is being assessed in three ongoing Phase 3 clinical trials under the SYNCHRONY program, targeting patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH, building on results from prior HARMONY and SYMMETRY studies.
This acquisition strategically enhances Novo Nordisk's portfolio within the metabolic disease area. Novo Nordisk already holds a significant position in chronic disease management, and the integration of Akero’s promising MASH pipeline, centered around EFX, represents a notable expansion into a therapeutic field with substantial unmet medical need globally. EFX is positioned as a potentially differentiated, best-in-class treatment for MASH, further solidifying the acquiring company's commitment to innovation in metabolic health.
The combination of Novo Nordisk's extensive global development capabilities and commercialization infrastructure with Akero's innovative clinical-stage assets is expected to significantly accelerate the progression of EFX through its remaining clinical development and towards market availability. Synergies from this acquisition are anticipated to streamline the path for EFX, thereby accelerating the delivery of a new therapeutic option for MASH patients. The combined entity aims to reinforce its leadership in serious metabolic diseases, driving forward solutions to improve patient outcomes.